Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia
Authors:
Open Access
- 1 June 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 13, 337-349
Abstract
Background: Immune thrombocytopenia (ITP) is well characterized in Western, European and other Asia-Pacific countries. Nevertheless, the clinical epidemiology, treatment pattern and disease outcome of ITP in Malaysia are still limited and not well known. Objective: This study aimed to describe the clinical epidemiology, treatment outcome and mortality of ITP patients in haematology tertiary multicentre in Malaysia. Methods: Clinical and laboratory data of newly diagnosed adults with ITP by a platelet count < 100 × 109/L from January 2010 to December 2020 were identified and analyzed. Results: Out of 500 incident ITP, 71.8% were females with a striking age preponderance of both genders among those aged 18– 29 years. The median age was 36 years. The median platelet count was 17.5 × 109/L, 23.0% had a secondary ITP, 34.6% had a Charlson’s score ≥ 1, 53.0% had bleeding symptoms including 2.2% intracranial bleedings (ICB). Helicobacter pylori screening was performed in < 5% of cases. Persistency and chronicity rates were 13.6% and 41.8%, respectively. Most (80.6%) were treated at diagnosis onset and 31.2% needed second-line treatment. Throughout the course of ITP, 11.0% of patients died; 3.0% and 8.0% with bleeding and non-bleeding related ITP. Conclusion: This study confirms the epidemiology of ITP is comparable with worldwide studies. Our incidence is high in the female, Malay ethnicity, primary ITP and events of cutaneous bleeding at ITP onset with 18– 29 years predominance age group for both genders. The frequency of persistent and chronic ITP is inconsistent with published literature. Corticosteroids and immunotherapies are the most prescribed first-line and second-line pharmacological treatments. Thrombopoietin receptor agonist medications (TPO-RAs) usage is restricted and splenectomy is uncommon. Our mortality rate is similar but ITP related bleeding death is fourth-fold lower than previous studies. Mortality risks of our ITP patients include age ≥ 60 years, male, severe bleeding at presentation, CCI≥ 1 and secondary ITP.Keywords
This publication has 74 references indexed in Scilit:
- Immune thrombocytopenia in children and adults: what's the same, what's different?Haematologica, 2011
- Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study GroupHaematologica, 2011
- Immune thrombocytopenia: No longer ‘idiopathic’Cleveland Clinic Journal of Medicine, 2011
- Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disordersVox Sanguinis, 2010
- The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsAmerican Journal of Hematology, 2010
- The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature reviewEuropean Journal of Haematology, 2009
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic reviewHaematologica, 2009
- Pathobiology of Secondary Immune ThrombocytopeniaSeminars in Hematology, 2009
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004